What a Biotech CTO Actually Owns

The single most common mistake we see in biotech CTO engagements starts with a job description copied from a SaaS company. A SaaS CTO owns product engineering, developer productivity, cloud spend, and site reliability. In a biotech that has no product to ship in the software sense, that scope is either irrelevant or actively distracting. The biotech CTO owns a different portfolio, one that sits at the intersection of scientific workflow, regulated quality systems, and enterprise IT.

In practice, the biotech CTO scope covers six areas that must be explicit in the engagement letter. The list matters because a fractional CTO cannot own everything at two or three days a week, and the board needs to see the trade-offs before signing the retainer.

Domain 1

Architecture Strategy

End-to-end target-state architecture across research computing, laboratory informatics (ELN, LIMS, ELN-adjacent tools), quality and regulatory systems, corporate IT, and cybersecurity. Decisions here compound for years.

Domain 2

Vendor Selection and Governance

Evaluation and contracting of major platform vendors: cloud (AWS, Azure, GCP), ELN/LIMS (Benchling, LabWare, STARLIMS, SampleManager), eQMS, RIM, and specialized bioinformatics tooling. Ongoing vendor management, renewals, and rationalization.

Domain 3

IT-Quality Partnership

The operating rhythm with the Head of Quality on computer system validation, 21 CFR Part 11 electronic records, Annex 11 compliance, and inspection readiness. This is where non-life-sciences CTOs typically fail.

Domain 4

Computing Infrastructure for R&D

High-performance computing, data lakes, bioinformatics pipelines, storage tiering for large-file science data, and the operating model for scientific compute (managed service vs. platform team vs. cloud vendor).

Domain 5

Cybersecurity Oversight

Owns the security roadmap even when a CISO or vCISO exists. Sets risk appetite, approves the security control framework, ensures OT/manufacturing systems are in scope, and reports material cyber risk to the board.

Domain 6

Roadmap Ownership

A rolling 18- to 24-month technology roadmap tied to clinical, manufacturing, and commercial milestones. Provides one authoritative sequencing view instead of six competing project lists.

Why the Biotech CTO Role Is Structurally Different

Three structural differences separate a biotech CTO engagement from the SaaS analog. First, the technology function serves science, not customers. The primary users are researchers, computational biologists, quality specialists, manufacturing engineers, and regulatory scientists, and their tools are governed by GxP requirements the CTO must fluently interpret.3 Second, decisions have long tails. A LIMS chosen today typically stays for a decade; a validation approach chosen at Phase 1 shapes inspection readiness through commercial launch. Third, the CTO is one of the primary interlocutors with regulators through IT, whether that is an FDA inspection touching computerized systems, an EMA Annex 22 review of AI, or an ICH E6(R3) audit of clinical systems.4

The Portfolio in Practice

A concrete way to think about the portfolio is to imagine three overlapping personas the biotech CTO must serve simultaneously. The first is the Chief Scientific Officer, who cares about lab productivity, data accessibility, computational power for genomics and structural biology, and the pace at which new instruments can be onboarded to the informatics stack. The second is the Head of Quality, who cares about validation, audit trails, electronic signatures, and inspection readiness across every system that touches product, patient, or regulatory data. The third is the CFO, who cares about total technology spend, contract commitments, and the trajectory of that spend against the runway.

A well-designed engagement structures the CTO’s weekly cadence to include a standing touchpoint with each of these three personas. In our observation, engagements that fail almost always fail because one of these three touchpoints is missing. A CTO who ignores the CSO will drift toward IT bureaucracy; a CTO who ignores the Head of Quality will build unvalidatable systems; a CTO who ignores the CFO will run out of runway on the roadmap. The two-day-per-week cadence is designed precisely to make all three touchpoints sustainable.

Modality-Specific Nuances

Within biotech, the specific modality shapes the CTO portfolio in ways that matter. A small-molecule biotech has a heavier commercial-manufacturing IT footprint and a longer runway of GMP inspection risk. A biologics company adds process development complexity and typically drives an earlier investment in bioprocess data platforms. A gene or cell therapy company inherits chain-of-identity and chain-of-custody data problems that no generic ERP handles well, and the CTO must own the integration between manufacturing, clinical, and patient-facing systems. A platform biotech, one whose core asset is a computational or data platform, needs a CTO who blends the R&D infrastructure sensibility with more traditional software product judgment. The engagement scope should reflect the modality explicitly rather than defaulting to a generic checklist.

Sakara Digital perspective. The most common failure mode we see is a CTO description that reads like it was written for an early-stage SaaS company: “own the engineering team, ship the roadmap, manage cloud spend.” That framing sets the CTO up to under-invest in the IT-Quality partnership and treat GxP as a compliance overlay rather than a first-class design constraint. Rewrite the JD to lead with quality partnership, science enablement, and regulatory-inspection readiness, and the right candidates surface.

The Fractional Model: Cadence, Duration, and Cost

The fractional model works because it separates the value of senior technology judgment from the volume of full-time work. In practice, the retained decisions of a CTO consume something like one to two days of concentrated attention per week; the remainder of a full-time CTO’s calendar is management overhead, meetings, and delegable execution. A well-scoped fractional engagement buys the decisions and delegates the execution to internal leaders, contractors, or partners.5

Typical Cadence

The industry median engagement is two days per week, which corresponds well to biotech at the pre-commercial and early-commercial stages. Two days provides room for a standing weekly leadership meeting, a quality council rhythm, deep work on a strategic decision, and reactive availability for the executive team. One day per week is tenable only for very early companies or for a strictly advisory scope. Three or more days per week starts to approach interim CTO territory, which is a different engagement class.6

2 days/wk
Median cadence for fractional CTO engagements across surveyed practices in 20266
12 months
Median engagement length, with most running 6 to 18 months at the fractional tier6
20-40%
Premium typically applied for healthtech, life sciences, and AI-applied engagements6

Typical Duration

Biotech engagements tend to run longer than the industry median. An 18- to 24-month window aligns to the natural milestones of a biotech: a Series B or C raise, a first GMP manufacturing campaign, an IND or CTA filing, or a first commercial launch. It also allows a full cycle of internal team-building, a completed vendor consolidation, and a real inspection or audit under the CTO’s operating model. Shorter engagements risk leaving the company halfway through a platform migration when the CTO exits.

Typical Cost

Fractional CTO retainers land in a wide but predictable range. In 2026, industry benchmarks put the median monthly retainer for a two-day-per-week engagement at approximately $15,000, with a broader range of $8,000 to $25,000 monthly depending on cadence and industry premium.7 Life sciences engagements typically sit at the upper end of that range because the required regulatory, quality, and platform expertise is scarcer than SaaS-generalist expertise.

Cost framing for the board. A full-time biotech CTO carries a fully loaded cost of $300,000 to $500,000 including base, bonus, equity, benefits, and recruiter fees. A fractional CTO at $15,000 to $22,000 per month across an 18-month engagement runs $270,000 to $396,000 total, which corresponds to roughly 30 to 50 percent of the cumulative full-time cost over the same window while the organization matures toward a permanent hire.

Transitional-to-Full-Time Paths

A fractional CTO is often the on-ramp for a full-time hire rather than a permanent operating model. Three transitional paths are common in biotech.

1

Bridge-and-recruit

The fractional CTO defines the target-state architecture, builds the roadmap and organizational structure, and then partners with the board on the search and hiring process for a permanent CTO. Typical bridge duration: 9 to 18 months.

2

Fractional-to-full-time conversion

The fractional CTO transitions into the full-time role at a natural inflection point, typically after a Series B or C. This works when the CTO has the appetite for the operating grind and the board is willing to compete on comp; it is the exception, not the rule.

3

Sustained fractional model

The company continues the fractional model beyond 24 months because it prefers the leverage. This works well for platform biotech companies, holdcos, or portfolio companies of a strategic investor who want senior technology leadership without competing for scarce talent.

The First 90 Days: Due Diligence, Quick Wins, and Strategy

The first 90 days set the tone for the entire engagement. In our practice, the pattern that works is a three-phase cadence: 30 days of technical due diligence, 60 days to secure meaningful quick wins alongside the diligence findings, and 90 days to deliver a formal technology strategy the board can vote on. This structure mirrors the disciplined post-acquisition playbooks used in pharma M&A integration, where technical misalignment is the single largest cause of integration failure.8

Days 0-30: Technical Due Diligence

The first 30 days should be almost entirely listening and inspecting. The output is a diagnostic that the CTO can defend to any auditor, board member, or successor.

The Diligence Inventory

  • Systems inventory: Every application in use across R&D, Quality, Manufacturing, Clinical, Regulatory, Commercial, Finance, and HR, mapped to owners, business criticality, GxP scope, and validation state.
  • Data assets and flows: Where scientific and regulatory data lives, who owns it, how it moves between systems, and where the pipelines are brittle or undocumented.
  • Cybersecurity posture: Identity and access management maturity, endpoint protection coverage, backup and recovery tested state, third-party risk program, and OT/manufacturing exposure.
  • Vendor and contract map: All active technology vendors, contract renewal dates, spend, and consolidation opportunities.
  • Team and organizational structure: Headcount, skills, reporting lines, open roles, and the effective decision rights across IT, Quality, and business functions.
  • Open regulatory findings: Any 483 observations, warning letters, EMA GMP inspection findings, or internal audit observations that touch computerized systems.

Diligence red flags to name explicitly. Unvalidated GxP systems in production, offline or manual “shadow” ELN and LIMS workarounds, expired backup restoration tests, orphaned admin accounts, vendors past end-of-support, and undocumented pipelines that only one person understands. Each of these becomes an inspection finding or an incident, and each is best surfaced in week two rather than month twelve.

Days 30-60: Quick Wins

Quick wins are the currency of trust. A fractional CTO who spends 90 days in diligence with no visible progress loses the room. The right quick wins are decisions the organization has been avoiding, low-risk cleanups that produce visible relief, and small structural changes that pay compounding dividends. Examples that consistently work in biotech include the following.

  • Retire two or three shelfware systems and cancel the associated renewals; this typically funds a chunk of the CTO’s own retainer within the first quarter.
  • Establish a weekly IT-Quality standing meeting with a shared risk register, replacing ad hoc coordination.
  • Kill an unvalidated shadow system and replace it with the validated path, on a compressed timeline the CTO personally sponsors.
  • Consolidate identity and access management under a single directory with MFA enforced across all GxP and financial systems.
  • Stand up a formal change advisory process for GxP-relevant changes, replacing the tribal-knowledge model.

Days 60-90: Strategy Formulation

The 90-day deliverable is a formal technology strategy: a one-page vision, a 12- to 18-month roadmap with major milestones and dependencies, a target-state architecture diagram, a cybersecurity risk statement, and a resource plan showing internal roles, vendor spend, and any additional fractional or contract help required. The strategy should be defensible to the board, the auditors, and the future full-time CTO, and it should be the anchor document that gets updated quarterly for the remainder of the engagement.9

What good looks like at day 90. The CEO can describe the technology strategy in two minutes. The Head of Quality can point to a standing operating rhythm with IT. The Head of Research can name the sequencing of platform investments and understands what is deferred. The board sees a cost trajectory that is defensible against the fully loaded alternative. That is the bar.

The Engagement Scope Template

The engagement letter is where most fractional CTO relationships either succeed or quietly fail. A vague scope invites scope creep on both sides. The template below has held up across multiple biotech engagements and is worth adapting rather than starting fresh.

Section What it contains Why it matters
Purpose One-paragraph statement of the business outcome the engagement supports (e.g., IND-enabling technology foundation, prepare for GMP manufacturing, post-Series-B scaling). Anchors every future scope discussion to a measurable milestone.
Reporting line Explicit reporting relationship to the CEO or COO, with dotted lines to the Head of Quality, Head of Research, and CFO. Clarifies decision rights and prevents the CTO from being routed to a mid-level manager.
In-scope domains The six domains from the previous section, with clarifying language on any that are shared with another executive. Names the trade-offs the board is signing up for at 2 days per week.
Out-of-scope Anything the fractional CTO will not own: software product management, day-to-day help desk, individual hiring decisions below director level, specific vendor negotiations delegated to procurement. Prevents scope creep and protects the fractional model.
Cadence Days per week, days on-site vs. remote, standing meetings the CTO attends, and expected board or investor touchpoints. Turns “2 days per week” into a defensible operating rhythm.
Deliverables The 30/60/90 outputs plus quarterly deliverables (roadmap update, budget input, board memo, quality council report, cyber risk statement). Makes the retainer defensible to the board.
Decision rights Explicit sign-off authority for architecture decisions, vendor selection, budget within threshold, hiring within IT, and inspection-response actions. Removes the ambiguity that kills fractional engagements.
Term and off-ramp Initial term (usually 6 or 12 months), renewal mechanism, notice period (30 to 60 days), and transition plan on exit. Protects both parties and enables a clean handoff to a full-time successor.
Confidentiality and IP Standard NDAs, IP assignment for work product, and explicit language on the CTO’s engagements with other biotech or life sciences clients. Boards and investors will ask; better to answer in advance.
Fees and expenses Monthly retainer, out-of-scope hourly rate, travel and expense policy, and equity if applicable. Clarity on what is included in the retainer vs. billed separately prevents disputes.

Quarterly Deliverables Framework

Beyond the 90-day setup, a well-run engagement produces a predictable set of quarterly deliverables. This is what makes the retainer defensible to a CFO reviewing spend each quarter and what makes the CTO impossible to forget when the CEO is presenting to the board.

Quarterly

Rolling Roadmap Update

An updated 18-month technology roadmap showing what shipped, what shifted, and what is next. One page, board-ready. This is the single most important document the CTO produces.

Quarterly

Board Technology Memo

A three- to five-page written memo covering material technology risks, decisions requiring board attention, spend trajectory, and progress against the roadmap. Written to survive the “what if the CTO leaves tomorrow” test.

Quarterly

Cybersecurity Risk Statement

A short quantified view of top cyber risks, mitigation status, and any material changes. Reflects the reality that pharma data breaches averaged $4.61 million per incident in 2025.10

Quarterly

Quality Council Report

The IT contribution to the site or company quality council: computer system validation status, open observations, planned changes, and inspection readiness. Written jointly with the Head of Quality.

Quarterly

Vendor and Spend Review

Contract renewals coming due, rationalization opportunities, and total technology spend trajectory. Cross-referenced against roadmap dependencies.

Quarterly

Talent and Org Review

Open roles, retention risk, org-structure adjustments, and progress toward the eventual full-time CTO handoff. Includes internal successor development if the intent is to promote from within.

The Annual Rhythm

Layered over the quarterly cadence, an annual rhythm should include one full architecture review, one full cybersecurity tabletop exercise, one budget planning cycle with the CFO, and one strategy refresh with the board. These are moments where the fractional CTO earns the multi-day-per-week rate through concentrated senior judgment rather than incremental work.

The biotech-specific overlay. Every annual rhythm should also include one mock inspection exercise for computerized systems, one cross-functional review of the GxP validation portfolio, and one review of the R&D data lake and analytics platform against emerging AI and machine learning workflows. These are the three areas where the biotech CTO’s judgment is hardest to replicate with contractors.

The Fractional-to-Full-Time Transition Plan

Most fractional CTO engagements end with a transition to a full-time CTO or a re-scoped continuation. Either outcome deserves a formal plan. The transition below is what we recommend for the bridge-and-recruit path, which is the most common in biotech.

Trigger Events That Signal Time to Transition

  • Funding milestone: Closing a Series C or later that adds a permanent technology executive to the org chart.
  • Manufacturing milestone: Standing up a first GMP manufacturing site or CMO relationship that requires resident, full-time technology leadership on-site.
  • Regulatory milestone: Filing an IND, CTA, or first BLA that shifts the technology stakes and inspection profile.
  • Team size: Reaching an internal IT and technology team that exceeds roughly 12 to 15 people, at which point the management burden alone justifies a full-time hire.
  • Commercial launch: First commercial launch, which typically pulls the technology function into daily operational tempo that fractional models cannot serve.

The Six-Month Transition Playbook

1

Month 1: Confirm the trigger and align the board

The fractional CTO presents to the board a formal recommendation to transition, including the specific trigger event, the profile of the target full-time CTO, the compensation range, and the estimated timeline. The board approves the search.

2

Month 2: Job description and search firm engagement

Write the JD anchored in the six-domain scope, not a generic template. Engage a life-sciences-focused executive search firm. The fractional CTO participates in candidate calibration.

3

Month 3-4: Candidate interviews and offer

The fractional CTO is a formal interviewer, focused on architecture judgment, GxP fluency, and cultural fit with the science-forward operating rhythm. The CEO owns the offer.

4

Month 5: Structured knowledge transfer

Overlap of the incoming and outgoing CTO for 30 to 60 days. Google’s own CTO transition famously involved a three-month overlap; a compressed version of that model works well here.11 Structured briefings on architecture, vendors, quality partnership, team dynamics, and open decisions.

5

Month 6: Advisory tail

The fractional CTO shifts to a defined advisory role of 4 to 8 hours per month for the following 3 to 6 months. This preserves institutional memory, gives the new CTO an unbiased sounding board, and enables clean escalation if the transition wobbles.

What to Hand Off in Writing

The written handoff artifact is a “CTO Operating Book” that includes the current roadmap, the architecture diagrams, the vendor register with renewal dates, the risk register, the org chart with retention notes, and a candid annotated list of open decisions and their history. This document is also the artifact that would let the board recover cleanly if a new hire did not work out. It is worth writing well.

The Sustained-Fractional Alternative

Not every biotech should transition to a full-time CTO. For platform-oriented biotechs, holding companies, and portfolio companies of a strategic investor, a sustained fractional model can outperform a permanent hire well past the 24-month mark. The signals that a sustained model is the right choice include a stable IT and technology headcount below 15, a manufacturing footprint that is fully outsourced to CMOs and CDMOs, a research operating model that leans heavily on external computational and analytics partners, and a board that values continuity of senior judgment over dedicated executive-team presence. In this scenario, the engagement letter should shift emphasis from “transition plan” to “annual renewal review” and add explicit language on knowledge continuity, backup coverage during the CTO’s other engagements, and IP handling across multiple client relationships.

Common Pitfalls Boards and Founders Should Avoid

A fractional CTO engagement can go wrong in ways that are almost always visible in the first 60 days. The following patterns come up in every conversation we have with boards and founders considering this model.

Buying advice instead of accountability. A fractional CTO is not a consultant delivering slides. They own outcomes. If the scope reads like a series of workshops, it is under-scoped. The retainer should buy senior judgment applied to real decisions with real accountability, including named quarterly deliverables.12

Under-weighting the IT-Quality partnership. A CTO who cannot fluently discuss computer system validation, 21 CFR Part 11, Annex 11, and computer software assurance is the wrong CTO for a biotech, regardless of otherwise impressive credentials. Test for this in interviews with a specific system-scenario question, not a general “tell me about your GxP experience.”

Ignoring cybersecurity. Biotech and pharma organizations sit in the top tier of ransomware and data-exfiltration targets, with recent public incidents at West Pharmaceutical Services in May 2026 and Inotiv in August 2025.1314 If the fractional CTO scope does not explicitly include cyber oversight, the board is buying a plaintiff-favorable governance gap.

Blurring lines with a vCIO or interim CTO. A fractional CTO differs from an interim CTO (short-term full-time gap-filler) and a virtual CIO (typically more IT-operations focused). Boards should be explicit about which role they are buying and adjust the scope, cadence, and cost accordingly.15

Skipping the transition plan. Boards frequently defer the transition-to-full-time conversation until it becomes urgent. Better to name the transition triggers on day one, in the engagement letter, and revisit them each quarter. That prevents the awkward moment when the fractional CTO becomes a bottleneck and no one has planned the exit.

Conclusion

A well-structured fractional CTO engagement is one of the highest-leverage moves a biotech board can make between Series A and commercial launch. It buys senior technology judgment, a defensible architecture, a partnership with Quality, and a coherent roadmap without the fully loaded cost of a permanent CTO. The prerequisites are a scope that reflects the true biotech-CTO portfolio, a cadence and duration that fit the milestones, and a written engagement that names the deliverables, decision rights, and transition triggers up front.

Sakara Digital works with pharma and biotech organizations building this kind of senior technology operating model, whether that means scoping a fractional CTO engagement, running an assessment before hiring one, or advising the board on the eventual transition to a full-time hire. If you are exploring how to structure a fractional CTO for your biotech and want an independent perspective on where to start, we are happy to have that conversation.